Androgen receptor splice variant 7 (AR‐V7) and AR full‐length (AR‐FL) as predictive biomarkers of therapeutic resistance: partners in crime?

The prostate cancer treatment armamentarium has expanded over the last decade to include taxane-based chemotherapies (docetaxel, cabazitaxel), sipulecel-T, radium-233, and newer androgen receptor (AR) signalling (ARS) inhibitors (abiraterone, enzalutamide, apalutamide). Despite these improvements, persistent ARS remains a key driver of prostate cancer progression after androgen-deprivation therapy (ADT), transition to castrate-resistant prostate...